Serum Carotenoids and α-Tocopherol and Risk of Nonmelanoma Skin Cancer
- Joanne F. Dorgan1,
- Naana A. Boakye2,
- Thomas R. Fears3,
- Rosemary L. Schleicher5,
- William Helsel6,
- Christa Anderson6,
- June Robinson7,
- Jere D. Guin8,
- Stuart Lessin1,
- Luke D. Ratnasinghe9 and
- Joseph A. Tangrea4
- 1Fox Chase Cancer Center, Philadelphia, Pennsylvania; 2Temple University Medical School, Philadelphia, Pennsylvania; 3Division of Cancer Epidemiology and Genetics and 4Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; 5Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, Georgia; 6Information Management Services, Silver Spring, Maryland; 7Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois; 8University of Arkansas for Medical Sciences, Little Rock, Arkansas; and 9National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas
- Requests for reprints:
Joanne Dorgan, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-5893; Fax: 215-214-1632. E-mail: jf_dorgan{at}fccc.edu
Abstract
Background: Carotenoids and tocopherols have been hypothesized to protect against cancer. Methods: We prospectively evaluated associations of several carotenoids and α-tocopherol with risk of nonmelanoma skin cancer using serum collected at baseline from 302 subjects in the Isotretinoin-Basal Cell Carcinoma Prevention Trial. All subjects had at least two BCCs in the 5 years prior to randomization. During 5 years of follow-up, 70 subjects did not develop a nonmelanoma skin cancer, 221 developed a BCC, and 85 developed a squamous cell carcinoma (SCC). Cox proportional hazards models were used to estimate risk ratios. Models were stratified by clinical center and gender and adjusted for age, solar damage, skin type, number of prior BCCs and/or SCCs, treatment group, body mass index, and serum low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol. Results: Risk of developing a subsequent BCC was not related to serum levels of any of the carotenoids measured or to α-tocopherol. Serum levels of α-carotene, β-carotene, lycopene, and α-tocopherol also were not independently related to risk of a subsequent SCC. However, serum lutein, zeaxanthin, and β-cryptoxanthin were positively related to SCC risk; risk ratios for subjects in the highest versus lowest tertiles of these micronutrients were 1.63 [95% confidence interval (95% CI) 0.88-3.01; P for trend = 0.01], 2.40 (95% CI 1.30-4.42; P for trend = 0.01), and 2.15 (95% CI 1.21-3.83; P for trend = 0.09), respectively. Conclusion: Additional research is needed on the relationship of carotenoids to SCC risk in the general population and in subsets of the population who are at increased risk.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted March 17, 2004.
- Received July 1, 2003.
- Revision received January 14, 2004.










